I wish I had some phenomenal insight or predictive abilities. In regard to your other post about the reverse split, I don't think it would be helpful unless we had an absolutely nailed in reason for it. I know a lot of times they talk about it bringing in a new level of investor, in some situations it allows for movement to a different exchange or different designation in the OTC, but it's not really used that way nearly 100% of the time. Given the company's inaccurate (intentional? unintentional? who knows) presentation of information, I think any R/S announcement would be met with speculation, ridicule, and likely a decent exodus of folks for whom this would further "confirm" their negative sentiments. I will be happy if O/S count remains steady and any increase is directly addressed (ideally preemptively) by the company explaining it's being utilized in a productive manner.
I do think there are a lot of positive things potentially happening here but it's taking a really long time for them to manifest. I love the number of distributors but the lack of revenues in the filed financials is a bit confusing and almost disconcerting to me. I expected a slow and gradual rise in revenues because a number of those distributors seem to be growing, expanding, and doing well. Unlike some, I don't expect the company to disclose the financial details of their contracts and distributorship agreements, but they could offer a range or somehow provide some insight for shareholders.
The UK variable has been explored up, down, and sideways. I sure do hope something manifests there but unlike others I'm not too optimistic. When I read that NHS document, I worry that the trust utilized PCT Europe to run the tests and verify the efficacy of hypochlorous acid then created their own HOCL production and distribution systems in-house. I don't know much about how patent law works with international borders, but even assuming that the patent on the tracking and RFID system holds in the UK the company doesn't have a patent on HOCL. So the hospital could just say "yea, this stuff works, we are going to produce it on site and put stickers on the bottles when we produce it" which isn't a violation of the patent in any way. The fact the trust published document talks about reinvesting their profits into the trust and that PCTL is no longer a shareholder in the PCT Europe filings is a bit concerning to me. I hope I'm wrong and I very well could be, but I'm not making my stand on the UK potential.
The oil and gas stuff is obviously the hot topic and from my layperson's reading of the phase 1 results it looks pretty hopeful. I have no idea how long the entirety of the testing process takes to get to a point where oil companies and producers are like "heck yea, that's legit, let me get some" but I hope some of them are willing to jump the gun based on initial testing results and not wait until all the phases are done. Patience is not something that OTC investors have in abundance, however, so that combined with the company's spotty history of PRs and consistent, accurate info makes for a volatile path in front of us.
I think the citrus application is really an underexplored area and I get the company doesn't have the resources to explore everything. They did testing in 2017 or 2018, good results, but the FDA requires some pretty high thresholds be met in general and especially if this would be the only application to address the issue plaguing the citrus industry. If the company could find the resources to explore that avenue, it would be great. Similar to the oil and gas stuff though, lots of phases and time which doesn't bode well because the need for money to get that is what leads to reverse splits, dilution, and other bad things.
I still think the money here is in the patent and they need the right marketing or sales team speaking to the right parties about it. The Annihilyzer was developed to address HAIs, which cost hospitals tens of billions of dollars a year in treatment they have to provide out of their own pockets. Ounce of prevention, pound of cure, all that. If the company were speaking to liability lawyers, hospital administrators, and folks who were thinking about liability and how to protect themselves in a lawsuit and save money, that's a way better approach to me than talking to medical personnel. Hell, they may have been talking to those people, but if they are I think they're doing a poor job of presenting the true benefit of the RFID tracking system - legal liability protection.
Probably a much longer answer than you wanted but it's my 52 cents on a Friday evening. I wish I was closing in on a couple million shares, I've got about half a million. Almost two years in, I sold for the first time (100,000 shares) a few weeks ago then bought it back at a slightly lower price. I worry if the first quarter revenues are a decline we will likely see some exodus also but those folks may be replaced pretty quickly because there are a lot of potential catalysts. There are also a lot of way worse OTC companies in a lot of ways than this one. Thanks for coming to my Ted Talk, I hope you have a good weekend :)
